: Vascular smooth muscle cell (SMC) proliferation is a central component of the pathophysiologic response to injury. Hepatoma derived growth factor (HDGF) is a potent SMC mitogen that is not normally present in the rat carotid, but becomes highly expressed in a nuclear pattern in the neointima after balloon injury. HDGF is also present in human vascular disease being co-expressed with PCNA in proliferating SMC in human atherosclerotic plaques, but the mechanisms by which HDGF produces SMC proliferation are unknown. This is due in part to the considerable controversy regarding the nuclear function of growth factors, in general and in the vascular wall in particular. Like HDGF, many growth factors in the vascular wall, including platelet derived growth factor (PDGF) and fibroblast growth factor (FGF), are nuclear targeted. However the nuclear function of growth factors, if any, has not been demonstrated. The overall goal of this grant proposal is to elucidate the nuclear mechanism(s) by which HDGF stimulates SMC proliferation in vitro and in response to injury. In our pilot studies, we found that single point mutations in a putative bipartite nuclear localization sequence block HDGF nuclear targeting and mitogenesis. We also now have evidence from a yeast two hybrid screen and co-immunoprecipitation (IP) studies that HDGF binds the key nuclear cell cycle regulatory protein p55cdc. Based upon these studies, we propose to determine the mechanisms regulating HDGF nuclear entry; whether nuclear entry is necessary for mitogenic function; and whether the nuclear function is regulation of the cell cycle control protein p55cdc. The significance of the proposed studies is that by linking HDGF nuclear entry to regulation of the cell cycle control protein p55cdc, a critical step in the nuclear action of HDGF is revealed and brings together for the first time the nuclear mechanism(s) of growth factor action in SMC. Indeed, understanding how HDGF regulates cell proliferation may provide additional insights into how growth factors regulate cellular growth in general.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL069938-05
Application #
6871258
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Program Officer
Srinivas, Pothur R
Project Start
2002-04-01
Project End
2007-02-28
Budget Start
2005-03-01
Budget End
2007-02-28
Support Year
5
Fiscal Year
2005
Total Cost
$408,750
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Parker, Donna K; Shen, Shuijie; Zheng, Jiang et al. (2017) Inhaled Treprostinil Drug Delivery During Mechanical Ventilation and Spontaneous Breathing Using Two Different Nebulizers. Pediatr Crit Care Med 18:e253-e260
Yang, Jun; Everett, Allen D (2009) Hepatoma-derived growth factor represses SET and MYND domain containing 1 gene expression through interaction with C-terminal binding protein. J Mol Biol 386:938-50
Yang, Jun; Everett, Allen D (2007) Hepatoma-derived growth factor binds DNA through the N-terminal PWWP domain. BMC Mol Biol 8:101
Narron, Jill V; Stoops, Tamara D; Barringhaus, Kurt et al. (2006) Hepatoma-derived growth factor is expressed after vascular injury in the rat and stimulates smooth muscle cell migration. Pediatr Res 59:778-83
Everett, Allen D; Ringel, Richard; Rhodes, John F et al. (2006) Development of the MAGIC congenital heart disease catheterization database for interventional outcome studies. J Interv Cardiol 19:173-7
Everett, Allen D; Narron, Jill V; Stoops, Tamara et al. (2004) Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 286:L1194-201